Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10456354 | SLAYBACK PHARMA LLC | Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate |
Oct, 2038
(15 years from now) | |
US11110054 | SLAYBACK PHARMA LLC | Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate |
Oct, 2038
(15 years from now) |
Drugs and Companies using GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE ingredient
Market Authorisation Date: 23 February, 2023
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11311554 | SLAYBACK PHARMA LLC | Pharmaceutical compositions of testosterone |
Mar, 2039
(16 years from now) |
Drugs and Companies using TESTOSTERONE CYPIONATE ingredient
Market Authorisation Date: 02 June, 2022
Treatment: NA
Dosage: SOLUTION;INTRAMUSCULAR
2
United States
1
India
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic